Physician profile
Jawan C Ayer Cole
NPI 1841273943
$84,864.98
in general payments reported to CMS, 2019-2025
44 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Obesity Medicine (Internal Medicine) provider received nationally (typical 2025 total: $202).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,240 · 2020: $9,265 · 2021: $18K · 2022: $20K · 2023: $17K · 2024: $15K · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $5,778 · Travel and Lodging: $1,798 · Long Term Medical Supply Or Device Loan: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,900.00 |
| Food and Beverage | $5,778.40 |
| Travel and Lodging | $1,798.16 |
| Long Term Medical Supply Or Device Loan | $333.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $36,249.49 | 2020-2022 | |
| Pfizer INC. | $28,187.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $9,778.46 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $2,490.29 | 2019-2023 | Imfinzi, Calquence, Lynparza |
| Emmaus Medical, INC. | $2,154.50 | 2019-2025 | Endari |
| Lilly USA, LLC | $1,736.24 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $693.11 | 2019-2022 | |
| Novo Nordisk INC | $377.55 | 2023-2025 | Wegovy |
| Aveo Pharmaceuticals, INC. | $298.90 | 2022-2024 | Fotivda |
| Incyte Corporation | $293.36 | 2019-2025 | Jakafi |
| Beigene USA, INC. | $267.53 | 2023-2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $207.50 | 2025 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $168.84 | 2023 | Eliquis |
| Alnylam Pharmaceuticals INC. | $165.70 | 2023-2024 | Amvuttra, Onpattro, Givlaari |
| Regeneron Healthcare Solutions, INC. | $158.44 | 2023-2024 | Libtayo |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawan Ayer Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.